Welcome back to another AJMC Insights series. In this episode titled, 'Setting the Stage: Treatment Selection and Eligibility in Follicular Lymphoma,' Ryan Haumschild, PharmD, MS, MBA, CPEL led the ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy. Good news for adults battling a specific type ...

Stage 2 lymphoma is localized, affecting lymph nodes or a single extranodal site on one diaphragm side, with a favorable prognosis. Diagnosis involves biopsies, blood tests, and imaging to confirm ...

AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed ...

The decision is based on data from the pivotal Phase III EPCORE FL-1 trial.

Epkinly plus R2 significantly improved PFS and response rates in relapsed/refractory follicular lymphoma, reducing disease progression risk by 79%. The Epkinly regimen achieved a 95% objective ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Note: Differences in patient/disease characteristics among groups (FL1-2, FL3A, FL3B and FL/DLBCL respectively) were analyzed using Fisher’s exact test for discrete variables and the Kruskal-Wallis H ...